The Phase 1 Feasibility Study has allowed Polibiotech to enhance their knowledge of the existing technologies and competition, assess the nutraceutical market size, customer segments, the existing nutraceuticals regulations and standards, as well as to establish the sound industralisation plan. The Phase 1 Feasibility Study showed, that in order to commercialise AGS, its capacity must be increased. And this will require some geometry optimizations, such as a new compactor and new a fraction device. In order to comply with the GMP standards Polibiotech must enhance the machine with in-line sensors system to check and validate the process dynamics and outputs have to trace how the material flows through the system.
The Feasibility Study showed that the AGS technology with its competitive advantages, puts Polibiotech in a strong position as the current granulation machines have a long new product R&D time (an average 4 months), very high production costs (due to high electricity usage, material waste and water usage) and NO possibility to renew the expiring patents. It is crucial that Polibiotech advances its current technology and commercial readiness levels to experience significant growth and development in the following years. A successful demonstration with a wide range nutraceuticals will help overcome the concerns about the continuous granulation systems.
The Feasibility Study also showed that the AGS machine will have a rapid market penetration and will reach a BEP in the first year. But to achieve Polibiotech desired goal and become a leader of the continues granulation system for nutraceutical, food and pharmaceutical, the technology must be optimised for reductions in costs of materials, efficiency and flowability.
